MAPT and Alzheimer disease: Overexpression of TYROBP can exacerbate tau-mediated neurodegeneration [133] and targeting of TYROBP in AD models is therapeutic, resulting in less severe neuritic dystrophy and attenuation of learning and behavioural impairment [85].